UPDATE August 7th
Scott Rocklage role in life science success
Scott Rocklage is a 60-year old doctor and business leader. He is the most sought-after scientist working in biochemical studies and entrepreneurship. He is currently serving as the managing partner of 5AM Ventures; a company that specializes in investment capital especially on study towards life science. He joined 5AM Ventures in 2003 and was later appointed as the managing partner in 2004.
His roles at 5AM Ventures is to conduct and oversee life science studies and collaborating with investment management companies.
Besides working in 5AM Venture, Rocklage uses his extensive experience in scientific research to help entrepreneurs, physicians, fellow scientists and even business leaders in honing their ideas to increase the possibility of discovering solutions to world’s deadliest diseases.
His work and education background
Scott has a degree in Chemistry from the University of California. He later obtained a Doctors of Philosophy degree in Chemistry at the prestigious Massachusetts Institute of Technology.
Besides studies, Dr. Scott has an extensive library of more than 100 papers published under his name not to mention some patents invention of drugs.
Dr. Scott has worked CEO of Cubist Pharmaceuticals, has served as the chairman and CEO of Nycomed Salutar, various leadership roles in Catalytica and Salutar among other exemplary leadership positions.
His experience in leadership has enabled him to steer 5AM Venture to higher heights. The company is now the most sort-after by those firms who wish to venture into life science industry. Scott has emphasized the use of modern technology in screening, preventing, and treating today’s medical challenges.
Dr. Scott is a no-nonsense person; he ensures that the company only recruits the most qualified staff will most relevant skills such as lawyers among others.
Through 5AM Ventures, Scott helps emerging businesses handle their operational activities with an eye of an expert. This helps the startup soar for success.
Dr. Scott is pleased of the advancement the scientist have had in finding Cancer’s cure. He comments that people living with the disease can now live longer.
He advises that one should never fear to step out of their comfort zone. He added that people should concentrate on what they understand best.
Dr. Rocklage is currently working as the Board Chairman of Achaogen, Relypsa, and Semprus. He also sits on the board of WaveRx, Pulmatrix.
His leadership strategies and over two decades in medical field opened the way to acceptance of three drugs by FDA (Omniscan, Cubicin, and Teslascan). He has also conducted successful drug trials in the laboratory.
Dr. Scott Rocklage has amassed over 30 years’ experience in healthcare management. His success in the chemical industry is mainly backed by his strong academic background and leadership abilities. Dr. Rocklage attained his B.S. in chemistry undergraduate degree from the University of California, Berkeley. He also holds a Ph.D. in chemistry from the Massachusetts Institute of Technology.
Throughout his career, Rocklage has worked for both small and big players in the biotechnology industry. Currently, he is the managing partner of 5AM Ventures, a venture capital company that supports emerging life science firms. He first joined as venture partner in 2003; a year later the company appointed him to be a managing partner. Between May to July 2016, Dr. Rocklage was at the helm of EPIRUS Biopharmaceuticals, Inc. as the Chief Executive Officer. In addition, he had a stint at Cubist Pharmaceuticals, a publicly-traded company, and Nycomed Salutar, a company that specializes in diagnostic imaging as Chairman and CEO. Dr. Rocklage’s work experience is further enhanced by R&D positions he served at Nycomed and Catalytica between 1986 and 1989.While working in R&D, he was able to innovate and develop high-end products.
Currently, apart from serving as a chairman of the board of directors in Rennovia, Inc., Dr. Rocklage also serves Achaogen, Inc. in the same capacity. Rennovia is a private company with specialty in bio-renewable chemicals and medical technology firm Kinestral Technologies. Besides, Rocklage serves as the Board Chairman of WaveRx, Relypsa, Semprus, Variation and Pulmatrix. He is also a member of Board of Associates at the Whitehead Institute. Previously, Rocklage served as the Executive Chairman of Miikana (acquired by EntreMed) and Ilypsa (acquired by Amgen).
The vast experience and leadership capabilities that Dr. Rocklage has gained in the management of healthcare companies helped him to successfully lead the development of Cubicin (an antibiotic treatment) by Cubist Pharmaceuticals, Inc., and its subsequent approval by FDA. He is also the lead man in the development and FDA approval of Omniscan™ and Teslascan® drugs manufactured by Nycomed Salutar, Inc. Also, Scott Rocklage has gained a good reputation in helping several drug candidates gain approval for clinical trials. He has over 30 US invention patents, and published over 100 peer reviewed articles.
While at Massachusetts Institute of Technology for PhD studies, Dr. Rocklage researched under Richard R. Schrock’s laboratory named after chemistry professor and Nobel Prize winner in Chemistry. His attachment to MIT helped him establish a strong, professional life and career. Scott Rocklage together with his loving wife offered to donate $250,000 for the revamping of Nano chemistry and nanotechnology lab space in Building 2. Indisputably, Rocklage is a success story in turning science into business. He has contributed a lot to the Science sector throughout his career.